| Dec'19 | Sep'19 | Jun'19 | Dec'18 | Sep'18 | Jun'18 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net income (loss) | ||||||
50,735 | -93,934 | -37,517 | -12,388 | -18,591 | -17,501 | |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||
Loss from Equity Method Investment in the Joint Venture | ||||||
-8,765 | -56,178 | -39,554 | -17,468 | -25,571 | -22,766 | |
Deferred income tax expense (benefit) | ||||||
15,242 | -13,622 | -2,184 | -5,080 | -6,783 | -4,801 | |
(Gain) Loss on Sale of Interests in the Joint Venture | ||||||
- | - | - | 0 | 197 | 464 | |
Changes in operating assets and liabilities: | ||||||
Due from the Joint Venture | ||||||
2,084 | 771 | 201 | 126 | 31 | 31 | |
Income taxes receivable | ||||||
-243 | -359 | 180 | 0 | -13,084 | -208 | |
Accrued expenses | ||||||
- | - | 168 | - | - | 31 | |
Due to the Joint Venture | ||||||
- | - | - | 1 | -9,871 | 208 | |
Cash flows from investing activities: | ||||||
Proceeds from sale of interests in Joint Venture | ||||||
- | - | - | 1,720 | 0 | 4,782 | |
Net cash provided by (used in) investing activities | ||||||
- | - | - | 1,720 | 0 | 4,782 | |
Cash flows from financing activities: | ||||||
Payments to acquire common stock | ||||||
- | - | - | 1,720 | 0 | 4,782 | |
Net cash provided by (used in) financing activities | ||||||
- | - | - | -1,720 | 0 | -4,782 | |